AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21327796 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study 19091807 — intervention group
Group type: EXPERIMENTAL
Intervention: Website use
Number of subjects: 228
Study 19091807 — intervention group
Group type: COMPARATOR
Intervention: Web pages related to behavioral feedback and communications
Number of subjects: 228
Study 16684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 196
Study 16684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Number of subjects: 196
Study 16684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil combined groups
Number of subjects: 196
Study 16684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg and 250 mg
Number of subjects: 196
Study 16684437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 15614594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (N=65)
Number of subjects: 100
Study 15614594 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (N=35)
Number of subjects: 100
Study 11379973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (specific details not provided)
Number of subjects: 45
Study 11379973 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment process
Number of subjects: 45
Study 8994756 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam (A/S)
Number of subjects: 90
Study 8994756 — intervention group
Group type: COMPARATOR
Intervention: imipenem/cilastatin (I/C)
Number of subjects: 90
Study 8430676 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency (CRI) patients
Number of subjects: 360
Study 3115786 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (1.7 g/m sq. t.i.d. added to conventional chemotherapy)
Number of subjects: 38
Study 3115786 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy only (control group of 32 patients)
Number of subjects: 38
Study 29362444 — intervention group
Group type: EXPERIMENTAL
Intervention: Active minocycline (100 mg b.i.d.) + active aspirin (81 mg b.i.d.) (M + A)
Number of subjects: 99
Study 29362444 — intervention group
Group type: EXPERIMENTAL
Intervention: Active minocycline + placebo aspirin (M + P)
Number of subjects: 99
Study 29362444 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-minocycline + active aspirin (A + P)
Number of subjects: 99
Study 29362444 — intervention group
Group type: COMPARATOR
Intervention: Placebo-minocycline + placebo aspirin (P + P)
Number of subjects: 99
Study 29362444 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 99
Study 29362444 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 99
Study 27599265 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person help to access services with follow-up telephone calls (navigation intervention)
Number of subjects: 1809
Study 27599265 — intervention group
Group type: COMPARATOR
Intervention: Written information on relevant community services (active control)
Number of subjects: 1809
Study 24033822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% niacinamide + 2% tranexamic acid (TXA) cream (test formulation; n = 21)
Number of subjects: 42
Study 24033822 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream (n = 21)
Number of subjects: 42
Study 22401534 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated Regret (AR) group
Number of subjects: 14520
Study 22401534 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) group
Number of subjects: 14520
Study 22401534 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire Control (QC) group
Number of subjects: 14520
Study 22401534 — intervention group
Group type: COMPARATOR
Intervention: No Questionnaire Control (NQC) group
Number of subjects: 14520
Study 20721920 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 114
Study 20721920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 19026251 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (MAS) (12.5 mg to 75 mg)
Number of subjects: 274
Study 19026251 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (MAS)
Number of subjects: 274
Study 19026251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 16830947 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated left ventricular segmentation method
Number of subjects: 0
Study 16830947 — intervention group
Group type: COMPARATOR
Intervention: Experienced radiologists (manual method)
Number of subjects: 0
Study 12663706 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy or a single cycle of perioperative chemotherapy for node-negative disease (1,275 women)
Number of subjects: 5352
Study 12663706 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy of at least 3 months' duration and/or tamoxifen for node-positive disease (4,077 women)
Number of subjects: 5352
Study 10972581 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy for 3 months
Number of subjects: 2906
Study 9370178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with anti-thymocyte globulin (ATG) 20 mg/kg/d for 7 to 14 days
Number of subjects: 100
Study 9370178 — intervention group
Group type: COMPARATOR
Intervention: CsA 8 mg/kg/d started immediately before surgery with diltiazem 60 mg sustained release twice daily
Number of subjects: 100
Study 9370178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with anti-thymocyte globulin (ATG)
Number of subjects: 100
Study 1583321 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5 x 10(8) cfu dose
Number of subjects: 324
Study 1583321 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5 x 10(9) cfu dose
Number of subjects: 324
Study 1583321 — intervention group
Group type: EXPERIMENTAL
Intervention: Second 5 x 10(9) cfu dose one week later
Number of subjects: 324
Study 1583321 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing vaccine dose to 5 x 10(9) cfu
Number of subjects: 324
Study 1583321 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vibriocidal titer
Number of subjects: 324
Study 3896281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (average daily dose 84 mg, range 40-160 mg)
Number of subjects: 14
Study 3896281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28144988 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief stress management intervention
Number of subjects: 72
Study 28144988 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 27139783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ABI
Number of subjects: 812
Study 27139783 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ABI
Number of subjects: 812
Study 25260025 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week version of the behavioral weight management program
Number of subjects: 162
Study 25260025 — intervention group
Group type: COMPARATOR
Intervention: 12-week version of the behavioral weight management program
Number of subjects: 162
Study 22352509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocoders that simulated aspects of cochlear implant processing
Number of subjects: 38
Study 22352509 — intervention group
Group type: COMPARATOR
Intervention: Recorded vowel‐consonant‐vowel tokens
Number of subjects: 38
Study 20587720 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB with omentectomy
Number of subjects: 22
Study 20587720 — intervention group
Group type: COMPARATOR
Intervention: LRYGB alone
Number of subjects: 22
Study 18689361 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (31% complex carbohydrate, 24% MUFAs)
Number of subjects: 12
Study 15778880 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg/day for 8 weeks)
Number of subjects: 36
Study 15778880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11836593 — intervention group
Group type: COMPARATOR
Intervention: Intravesical instillation of anticancer drug alone (method A)
Number of subjects: 196
Study 11836593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation plus oral chemotherapy (doxifluridine, 5'‐DFUR) (method B)
Number of subjects: 196
Study 10362181 — intervention group
Group type: EXPERIMENTAL
Intervention: Active counterpulsation (active CP)
Number of subjects: 139
Study 10362181 — intervention group
Group type: COMPARATOR
Intervention: Inactive counterpulsation (inactive CP)
Number of subjects: 139
Study 8750168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/d for 1 week)
Number of subjects: 0
Study 8750168 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 microg/d for 1 week)
Number of subjects: 0
Study 8750168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8750168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin stimulation test
Number of subjects: 0
Study 8750168 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 mucosal generation
Number of subjects: 0
Study 1897264 — intervention group
Group type: COMPARATOR
Intervention: Western therapy (dihydrochlorothiazide and atenolol)
Number of subjects: 50
Study 1897264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese traditional therapy (mixtures of nine herbs and other ingredients)
Number of subjects: 50
Study 6275999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime alone (125 patients)
Number of subjects: 249
Study 6275999 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/clindamycin (124 patients)
Number of subjects: 249
Study 31471753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT angiography using ASiR-V
Number of subjects: 80
Study 31471753 — intervention group
Group type: COMPARATOR
Intervention: Standard CT angiography
Number of subjects: 80
Study 31361682 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Number of subjects: 42
Study 31361682 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 42
Study 28113240 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery over 12 weeks
Number of subjects: 8
Study 26735385 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHW) trained to promote physical activity during home visits
Number of subjects: 176
Study 26735385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 176
Study 24982375 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg doxorubicin loaded Super Absorbent Polymer microspheres
Number of subjects: 25
Study 24982375 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin loaded Super Absorbent Polymer microspheres
Number of subjects: 25
Study 24982375 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg doxorubicin loaded Super Absorbent Polymer microspheres
Number of subjects: 25
Study 24982375 — intervention group
Group type: COMPARATOR
Intervention: 0 mg (bland embolic)
Number of subjects: 25
Study 24982375 — intervention group
Group type: COMPARATOR
Intervention: Bland embolic vs drug-loaded groups
Number of subjects: 25
Study 24982375 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 25
Study 22217100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (600 mg)
Number of subjects: 54
Study 22217100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (20 mg)
Number of subjects: 54
Study 22217100 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 54
Study 22217100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19174719 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation for diabetic macular edema
Number of subjects: 323
Study 19174719 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics (CSMT, age, fluorescein leakage)
Number of subjects: 323
Study 17845167 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% malathion gel (30 minutes application)
Number of subjects: 172
Study 17845167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovide Lotion (0.5% malathion)
Number of subjects: 172
Study 17845167 — intervention group
Group type: COMPARATOR
Intervention: Nix Crème Rinse (1% permethrin)
Number of subjects: 172
Study 15447735 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once a day for four days)
Number of subjects: 10
Study 15447735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11678783 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml, double strength, three times a day for 2 days)
Number of subjects: 10
Study 11678783 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 9834260 — intervention group
Group type: EXPERIMENTAL
Intervention: SR27417A (10 mg/day)
Number of subjects: 151
Study 9834260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7912044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (100, 30, and 6 ng.kg‐1.min‐1 for 10 min, 15 min, and thereafter, respectively)
Number of subjects: 14
Study 7912044 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 14
Study 7912044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 14
Study 2732065 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cardiovascular disease risk reduction intervention
Number of subjects: 206
Study 2732065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 1103617 — intervention group
Group type: EXPERIMENTAL
Intervention: Inline, 0.45‐mum membrane filter
Number of subjects: 146
Study 1103617 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered fluids
Number of subjects: 146
Study 1103617 — intervention group
Group type: COMPARATOR
Intervention: Buffered infusion fluid or 24-hour change of administration set
Number of subjects: 146
Study 1103617 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with inline filters
Number of subjects: 146
Study 31202024 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-step stair climb test (11-SCT)
Number of subjects: 57
Study 31202024 — intervention group
Group type: COMPARATOR
Intervention: Descending stair time during the 11-SCT
Number of subjects: 57
Study 27376875 — intervention group
Group type: EXPERIMENTAL
Intervention: Autosuggestion
Number of subjects: 60
Study 27376875 — intervention group
Group type: COMPARATOR
Intervention: Control (no autosuggestion)
Number of subjects: 60
Study 26203826 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg tabalumab every 4 weeks (120/Q4W)
Number of subjects: 1004
Study 26203826 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg tabalumab every 2 weeks (90/Q2W)
Number of subjects: 1004
Study 26203826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study 24113125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) rTMS (≤ 1 Hz) applied to the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 249
Study 24113125 — intervention group
Group type: COMPARATOR
Intervention: High-frequency (HF) rTMS (10‐20 Hz) applied to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 249
Study 21298412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia
Number of subjects: 16
Study 21298412 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia
Number of subjects: 16
Study 19187638 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK3 mRNA levels in TOF group
Number of subjects: 30
Study 19187638 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK3 protein levels in TOF group
Number of subjects: 30
Study 16481387 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (daily doses of </=500 microg)
Number of subjects: 0
Study 16481387 — intervention group
Group type: COMPARATOR
Intervention: Nasal corticosteroids
Number of subjects: 0
Study 15170517 — intervention group
Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan haemorrhoidectomy (group A)
Number of subjects: 200
Study 15170517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferguson haemorrhoidectomy (group B)
Number of subjects: 200
Study 15170517 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study 11595086 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) applied in 300 ms intermittent pulses at 40 Hz, 15-20 mA for 8 hours a day up to 14 days of coma
Number of subjects: 10
Study 11595086 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 10
Study 9840852 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar block
Number of subjects: 30
Study 9840852 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bupivacaine infiltration
Number of subjects: 30
Study 9840852 — intervention group
Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 30
Study 7986147 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions (allogeneic, autologous, or both)
Number of subjects: 420
Study 7986147 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusions
Number of subjects: 420
Study 2648816 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery for 2 s (fixed duration cautery)
Number of subjects: 35
Study 2648816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cautery until visible necrosis of the polyp base (variable duration cautery)
Number of subjects: 35
Study 2648816 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible necrosis achieved
Number of subjects: 35
Study 2648816 — intervention group
Group type: EXPERIMENTAL
Intervention: No visible necrosis
Number of subjects: 35
Study 29569536 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt intervention
Number of subjects: 1835
Study 28796990 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis (GMA) with the Adacolumn as remission induction therapy
Number of subjects: 77
Study 25924545 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Flap Approach (SFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Number of subjects: 28
Study 25924545 — intervention group
Group type: COMPARATOR
Intervention: Double Flap Approach (DFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Number of subjects: 28
Study 25924545 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Flap Approach (SFA)
Number of subjects: 28
Study 25924545 — intervention group
Group type: COMPARATOR
Intervention: Double Flap Approach (DFA)
Number of subjects: 28
Study 25924545 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Flap Approach (SFA) and Double Flap Approach (DFA)
Number of subjects: 28
Study 23470303 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid supplementation (1000 mg daily for 14 days)
Number of subjects: 12
Study 23470303 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 12
Study 21712276 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial radiofrequency (RF) catheter ablation
Number of subjects: 43
Study 21712276 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial RF catheter ablation
Number of subjects: 43
Study 18573712 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 1553
Study 14622079 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 132
Study 14622079 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) with significant other
Number of subjects: 132
Study 14622079 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 132
Study 10606851 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium nitrite co‐applied with 5% salicylic acid under occlusion
Number of subjects: 0
Study 10606851 — intervention group
Group type: COMPARATOR
Intervention: Identical cream with 5% salicylic acid, omitting sodium nitrite
Number of subjects: 0
Study 8682016 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation and secondary prevention programme lasting 3 years after acute myocardial infarction
Number of subjects: 375
Study 8682016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study 2228838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g iv
Number of subjects: 12
Study 2228838 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g iv
Number of subjects: 12
Study 121165 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (daily at least 1.1010 granulocytes per square meter from the last day of treatment until the 12th day of aplasia)
Number of subjects: 50
Study 121165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic granulocyte transfusions, eligible for transfusions as clinically indicated)
Number of subjects: 50
Study 31076461 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0
Study 31076461 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study 28234436 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate discontinuation of prior antipsychotics at baseline
Number of subjects: 33
Study 28234436 — intervention group
Group type: COMPARATOR
Intervention: Gradual discontinuation of prior antipsychotics by reducing 25% each week
Number of subjects: 33
Study 28234436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Immediate and Gradual)
Number of subjects: 33
Study 25636135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bathing for 8 weeks
Number of subjects: 37
Study 24174681 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-tACS during motor imagery
Number of subjects: 0
Study 24174681 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tACS at rest
Number of subjects: 0
Study 24174681 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21846904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 196
Study 21846904 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 196